8413 related articles for article (PubMed ID: 1790141)
1. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
[TBL] [Abstract][Full Text] [Related]
2. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
3. Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
Sedlmayr P; Rabinowich H; Winkelstein A; Herberman RB; Whiteside TL
Br J Cancer; 1992 Feb; 65(2):222-8. PubMed ID: 1739621
[TBL] [Abstract][Full Text] [Related]
4. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
5. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
6. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
Koyama S
J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison of the activity of human lymphokine-activated killer (LAK) cells and adherent LAK cells.
Jemma C; Cignetti A; Geuna M; Caretto P; Vai S; Forni G
J Immunother (1991); 1991 Jun; 10(3):189-99. PubMed ID: 1868043
[TBL] [Abstract][Full Text] [Related]
8. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
9. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
10. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
11. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
12. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
[TBL] [Abstract][Full Text] [Related]
13. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
15. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
16. Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia.
Lotzová E; Savary CA; Totpal K; Schachner J; Lichtiger B; McCredie KB; Freireich EJ
Leuk Res; 1991; 15(4):245-54. PubMed ID: 2030606
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
Belldegrun A; Uppenkamp I; Rosenberg SA
J Urol; 1988 Jan; 139(1):150-5. PubMed ID: 3257274
[TBL] [Abstract][Full Text] [Related]
18. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies.
Suck G; Oei VY; Linn YC; Ho SH; Chu S; Choong A; Niam M; Koh MB
Exp Hematol; 2011 Sep; 39(9):904-14. PubMed ID: 21703984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]